Resected Stage II-III Kirsten rat sarcoma virus oncogene homolog glycine 12 to Cysteine (KRAS G12C) -Positive Non-Small Cell Lung Cancer
Conditions
Brief summary
DFS defined as the time from randomization to the first documented recurrence of disease or new primary NSCLC as determined by the investigator through use of an integrated assessment of radiographic data, biopsy sample results (if clinically feasible), and clinical status or death from any cause, whichever occurs first
Detailed description
Overall Survival (OS) defined as the time from randomization to death from any cause, 2-year and 3-year DFS rates as assessed by the investigator, Incidence and severity of adverse events, including, but not limited to treatment emergent adverse events, serious adverse events, and deaths
Interventions
Sponsors
F. Hoffmann-La Roche AG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DFS defined as the time from randomization to the first documented recurrence of disease or new primary NSCLC as determined by the investigator through use of an integrated assessment of radiographic data, biopsy sample results (if clinically feasible), and clinical status or death from any cause, whichever occurs first | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS) defined as the time from randomization to death from any cause, 2-year and 3-year DFS rates as assessed by the investigator, Incidence and severity of adverse events, including, but not limited to treatment emergent adverse events, serious adverse events, and deaths | — |
Outcome results
None listed